Loading
companiesCompany
Century Therapeutics
Century makes off-the-shelf cell therapies from induced pluripotent stem cells that are engineered to hide from the patient's immune system. Its main focus is now type 1 diabetes, with a CD19 CAR T-like product for cancer and autoimmune disease due to enter the clinic in 2026.
Overview
Century Therapeutics develops allogeneic, induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune disease and cancer. Lead programme CNTY-813 is an iPSC-derived islet replacement therapy for type 1 diabetes with an IND submission planned for the fourth quarter of 2026 following a pre-IND meeting with the FDA. CNTY-308 is a CD19-targeted CAR-iT (iPSC-derived T cell) therapy incorporating the company's Allo-Evasion 5.0 immune-evasion edits, on track to enter the clinic in 2026. The company reported $197.2 million in cash and investments at 30 June 2026 with runway into the first quarter of 2029. Century is headquartered in Philadelphia and trades on Nasdaq as IPSC.
Headquarters
Philadelphia, PA, US
Funding
All startupsPublic
Investors
Type
Cell therapy · IPSC
Stage
Public
Website
Notes
top- Strategic emphasis has shifted to type 1 diabetes; oncology exposure is via CNTY-308 (CD19 CAR-iT). IPO round not sourced (June 2021 8-K did not state proceeds).
Similar pages
- CompanyCaribou Biosciences
Shares Allogeneic cell banks: one donor, hundreds of doses, Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy.
- CompanyImugene
Shares Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy.
- CompanyFate Therapeutics
Shares Allogeneic cell banks: one donor, hundreds of doses, Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy.
- CompanyPoseida Therapeutics
Shares Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy.
- PersonWaseem Qasim
Shares Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy.
- PersonJae H. Park
Shares CD19, CAR-T cell therapy.
- CompanyCellectis
Shares Allogeneic cell banks: one donor, hundreds of doses, Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
- CompanyAllogene Therapeutics
Shares Allogeneic cell banks: one donor, hundreds of doses, Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy.